“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of ...

SMART control of CAR T cells is advancing cancer immunotherapy by improving precision, safety, and adaptability. Why Smart ...

The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers. Promising initial testing results, ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Figure 2: Challenges and emerging advancements in CAR-T therapy. The schematic representation outlines the major limitations associated with CAR-T treatment, including various toxicities, limited ...

The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...